Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RESEARCH TOOLSreports
Holding RXRX?
Track your performance easily
RXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.97 - $15.74
Previous Close$5.92
Volume3.99M
Average Volume (3M)5.75M
Market Cap
$1.67B
Enterprise Value$1.29B
Total Cash (Recent Filing)$474.34M
Total Debt (Recent Filing)$89.88M
Price to Earnings (P/E)―
Beta3.16
Next Earnings
Nov 06, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding281,108,594
10 Day Avg. Volume5,159,888
30 Day Avg. Volume5,751,438
Standard Deviation0.29
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.08
Price to Sales (P/S)34.23
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.06
Enterprise Value/Gross Profit647.07
Enterprise Value/Ebitda-7.42
Forecast
1Y Price Target
$10.17Price Target Upside66.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Recursion Pharmaceuticals News
PremiumCompany Announcements
Recursion Pharmaceuticals Proposes Strategic Exscientia Merger
Bulls Say, Bears Say
Bulls Say
Financial PerformanceWith cash runway into 2027, Recursion has multiple opportunities for value creation.
Partnerships And CollaborationsThe deal adds 3 new pharma partnerships (BMS, Sanofi and Merck KGaA) which could altogether generate ~$200M in near-term milestones.
Technology And InnovationRecursionOS continues to expand and accelerate knowledge creation with support from the recently upgraded supercomputing capabilities of Biohive-2.
Bears Say
Clinical TrialsThe lack of PRO benefits and generally limited nature of the efficacy detail likely pressured RXRX.
Financial PerformanceThe current cash position (~$296mm at the end of 1Q24) and burn (~$110mm Opex in 1Q24) warranted a raise.
Investor SentimentRXRX shares are trading down (-16.3%; NBI: -0.8%) on the back of phase 2 readout for the company’s small molecule REC-994 being developed for cerebral cavernous malformation (CCM).
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $4.97 and its highest was $15.74 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Currently, no data Available
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 51 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.384 by -$0.016.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -$0.33.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 275,069,600 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.384. Following the earnings report the stock price went up 4.239%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Among the largest hedge funds holding Recursion Pharmaceuticals’s share is ARK Investment Management LLC. It holds Recursion Pharmaceuticals’s shares valued at 211M.
---
Recursion Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.17 (66.18% Upside)
$10.17 (66.18% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 19.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.58%
12-Months-Change
Fundamentals
Return on Equity
-71.18%
Trailing 12-Months
Asset Growth
16.37%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
---
RXRX Company Deck
---
RXRX Earnings Call
Q2 2024
0:00 / 0:00
---
RXRX Stock 12 Month Forecast
Average Price Target
$10.17
▲(66.18% Upside)
Technical Analysis
Best Analysts Covering RXRX
1 Year
---